^
    over2years
    Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. (PubMed, ESMO Open)
    Combination of a TA-MUC1-targeting antibody and an EGFR-targeting antibody is safe and feasible. Interesting antitumor activity was observed in heavily pretreated patients. Future studies should test this combination together with chemotherapy and explore the potential of sTA-MUC1 as a companion biomarker for further development of the combination.
    P1 data • Clinical Trial,Phase I • Journal
    |
    MUC1 (Mucin 1)
    |
    EGFR positive
    |
    PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)
    3years
    Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. (PubMed, ESMO Open)
    Gatipotuzumab switch maintenance therapy does not improve outcome in TA-MUC1-positive ovarian cancer patients.
    Clinical • P2 data • Journal
    |
    MUC1 (Mucin 1) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    TA-MUC1 positive
    |
    PankoMab-GEX (gatipotuzumab)
    over3years
    [VIRTUAL] Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors. (ASCO 2021)
    Combination of TA-MUC1 and EGFR targeting antibody is safe and feasible . Interesting anti-tumor activity was observed in heavily pretreated CRC and NSCLC patients . Levels of soluble TA-MUC1 may have predictive value and potentially be a companion biomarker for further development of the combination
    Clinical • P1 data
    |
    MUC1 (Mucin 1)
    |
    Vectibix (panitumumab) • PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)
    over3years
    [VIRTUAL] Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors. (ASCO 2021)
    Combination of TA-MUC1 and EGFR targeting antibody is safe and feasible . Future studies should test this combination together with chemotherapy
    Clinical • P1 data
    |
    MUC1 (Mucin 1)
    |
    Vectibix (panitumumab) • PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)
    4years
    PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=216, Completed, Glycotope GmbH | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    PankoMab-GEX (gatipotuzumab)
    almost5years
    Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. (PubMed, Ann Oncol)
    No abstract available
    Clinical • P1 data • Journal • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    PankoMab-GEX (gatipotuzumab) • CetuGEX (tomuzotuximab)